PODD

AI Research

Omnipod 5 recall for 1.5% of pods → Q4 revenue surges 31% to $783.8M; Strong Buy consensus

Insulet initiated a voluntary Medical Device Correction on March 12, 2026 for specific Omnipod 5 Pod lots due to potential insulin under-delivery, affecting approximately 1.5% of annual production with 18 serious adverse events reported. Despite the recall concern, the company reported strong Q4 2025 and full-year results with Q4 revenue of $783.8M (+31.2%) and FY2025 revenue of $2.7B (+30.7%), alongside a $350M share repurchase authorization increase. Twenty-four analysts recommend buying with a Strong Buy consensus and average price target of $354, implying ~50% upside from current levels.